Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Egfr Tyrosine Kinase Inhibitor”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Looking for participantsNCT06302621
What this trial is testing

Pemigatinib + Afatinib in Advanced Refractory Solid Tumors

Who this might be right for
Advanced Solid TumorUnresectable Solid TumorMetastatic Solid Tumor+1 more
Massachusetts General Hospital 32
Testing effectiveness (Phase 2)Study completedNCT00044343
What this trial is testing

GW572016, An Oral Drug For Colorectal Cancer Patients Having Prior Therapy With 5-FU Plus CPT-11 And/Or Oxaliplatin

Who this might be right for
Colorectal Cancer
GlaxoSmithKline 80
Early research (Phase 1)Active Not RecruitingNCT02609776
What this trial is testing

Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer

Who this might be right for
Non-Small-Cell Lung Cancer
Janssen Research & Development, LLC 751
Testing effectiveness (Phase 2)Ended earlyNCT01522612
What this trial is testing

Colorectal Cancer (CRC) Cetuximab Elderly Frail

Who this might be right for
Colorectal Cancer Metastatic
European Organisation for Research and Treatment of Cancer - EORTC 5
Early research (Phase 1)Study completedNCT00098501
What this trial is testing

CCI-779 and EKB-569 in Treating Patients With Advanced Solid Tumors

Who this might be right for
Unspecified Adult Solid Tumor, Protocol Specific
National Cancer Institute (NCI) 42
Testing effectiveness (Phase 2)Ended earlyNCT00445549
What this trial is testing

Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Ovarian NeoplasmsFallopian Tube NeoplasmsPeritoneal Neoplasms
National Cancer Institute (NCI) 12
Testing effectiveness (Phase 2)Ended earlyNCT01526928
What this trial is testing

Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients

Who this might be right for
Locally Advanced or Metastatic Non Small Cell Lung Cancer
Clovis Oncology, Inc. 612
Testing effectiveness (Phase 2)Looking for participantsNCT02491099
What this trial is testing

A Phase II Evaluation of Afatinib in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma

Who this might be right for
HER2/Neu+ Uterine Serous Carcinoma
Yale University 50
Testing effectiveness (Phase 2)Study completedNCT01892527
What this trial is testing

Study of Tivantinib (ARQ 197) Plus Cetuximab in EGFR Inhibitor-Resistant MET High Subjects

Who this might be right for
Colorectal Cancer MetastaticC-met Overexpression
Armando Santoro, MD 43
Large-scale testing (Phase 3)Study completedNCT02864251
What this trial is testing

Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy

Who this might be right for
Non-Small-Cell Lung Carcinoma
Bristol-Myers Squibb 367
Testing effectiveness (Phase 2)Ended earlyNCT00479856
What this trial is testing

Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer

Who this might be right for
Relapsed Breast CancerNeoplasms, Breast
GlaxoSmithKline 9
Large-scale testing (Phase 3)Not Yet RecruitingNCT07754123
What this trial is testing

Phase III Study of HS-10504 Versus Platinum-Based Doublet Chemotherapy in Patients With C797S+ NSCLC

Who this might be right for
Advanced or Metastatic NSCLC
Jiangsu Hansoh Pharmaceutical Co., Ltd. 206
Early research (Phase 1)Active Not RecruitingNCT05364073
What this trial is testing

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)Metastatic Non-Small Cell Lung CancerAdvanced Non-Small Cell Lung Cancer+3 more
ArriVent BioPharma, Inc. 160
Early research (Phase 1)Study completedNCT00903734
What this trial is testing

An Umbrella, Modular Study Based on Epidermal Growth Factor Receptor (EGFR) Mutation Status

Who this might be right for
Advanced Cancers
M.D. Anderson Cancer Center 16
Testing effectiveness (Phase 2)Study completedNCT00045487
What this trial is testing

Erlotinib in Treating Patients With Advanced Kidney Cancer

Who this might be right for
Kidney Cancer
The University of Texas Health Science Center at San Antonio 41
Early research (Phase 1)Looking for participantsNCT06046495
What this trial is testing

The Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Avistone Biotechnology Co., Ltd. 81
Large-scale testing (Phase 3)Ended earlyNCT02186301
What this trial is testing

TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy

Who this might be right for
Non-Small Cell Lung Cancer
Clovis Oncology, Inc. 100
Testing effectiveness (Phase 2)UnknownNCT01932229
What this trial is testing

An Open Label Study of BIBW 2992/Afatinib in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib

Who this might be right for
NSCLC
Sheba Medical Center 20
Not applicableStudy completedNCT03133234
What this trial is testing

Effect of Osimertinib in Ethnic Chinese With EGFR and T790M Mutated NSCLC

Who this might be right for
T790M Positive NSCLC Patients
AstraZeneca 47
Testing effectiveness (Phase 2)Study completedNCT00054275
What this trial is testing

Erlotinib Plus Docetaxel in Treating Patients With Stage IV or Recurrent Breast Cancer

Who this might be right for
Breast Cancer
Paula Silverman, MD 39
Next Page